Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series

Table 1

Patient’s characteristics.

	N	%
No. of patients	41	100
Median age	54 (33–75)
PS (ECOG)
0	30	73
1	11	27
Histology
Ductal	36	88
Lobular	5	12
Hormonal Receptor status
EgR+PgR+	24	58
EgR+PgR−	4	10
EgR−PgR+	1	2
EgR−PgR−	12	29
HER2 Status
3+	32	78
2+ CISH+	9	22
Stage at diagnosis
I	3	7
IIA	8	20
IIB	2	5
IIIA	16	39
IIIB	5	12
IIIC	5	12
IV	2	5
Metastatic site
𝐍𝐨𝐝𝐚𝐥𝐢𝐧𝐯𝐨𝐥𝐯𝐞𝐦𝐞𝐧𝐭±𝐬𝐨𝐟𝐭𝐭𝐢𝐬𝐬𝐮𝐞	7	17
As bone only	3	7
1 visceral site (liver, lung, and pleura) only	3	7
Metastatic sites ≥𝟐	28	69
Metastasis to CNS	6	14
Prior adjuvant CT	38	92
Adjuvant trastuzumab	3	7
Prior CT for metastatic disease	41	100
1 regimen	5	12
2 regimens	11	28
≥3 regimens	25	60
𝐏𝐫𝐢𝐨𝐫𝐭𝐫𝐚𝐬𝐭𝐮𝐳𝐮𝐦𝐚𝐛−𝐛𝐚𝐬𝐞𝐝𝐂𝐓	37	90
𝐏𝐫𝐢𝐨𝐫𝐥𝐚𝐩𝐚𝐭𝐢𝐧𝐢𝐛+𝐜𝐚𝐩𝐞𝐜𝐢𝐭𝐚𝐛𝐢𝐧𝐞	17	41

ECOG: Eastern Cooperative Oncology Group, EgR: Estrogen Receptor, PgR: Progesteron Receptor, CISH: Chromogenic In Situ Hybridisation, CT: Chemotherapy, CNS: Central Nervous System.